Navigation Links
U.S. Oncology Initiates Complete Phase Ib Trial of Brostallicin Combination Therapy in Advanced Solid Tumors
Date:10/18/2007

Onco-genomic guided trial design may increase probability of tumor response

and accelerates drug development

SEATTLE, Oct. 18 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTAX: CTIC) and Systems Medicine, LLC (SM), a wholly-owned subsidiary of CTI, today announced the enrollment of the first patient to its complete phase Ib trial of brostallicin used in combination with either bevacizumab or irinotecan, for patients with advanced solid tumors. Combining brostallicin with either bevacizumab or irinotecan is based on existing preclinical data that strongly supports taking these combinations into the clinic. A third treatment arm, which will include brostallicin in combination with an anticancer agent to be identified, will be added to the study. The agent will be identified from ongoing pharmacogenomic investigations using genomic-based search strategies to identify agents that are synergistic with brostallicin.

The trial, being conducted at multiple U.S. Oncology sites, is unique because of the novel "complete" phase I trial design and that genomic-driven discovery is being used to identify at least one of the agents for use with brostallicin. The study design combines a new drug with existing therapies, selected based on genomic profiling, to increase the probability of seeing tumor responses in phase I and may enhance the overall success of the development program. The complete phase I trial design, which was first reported at the 2007 Annual Meeting of the American Society for Clinical Oncology (ASCO), allows several combination phase 1 trials be conducted simultaneously.

"Most new drug approvals in development are in combination with existing regimens by phase III. By utilizing the complete phase I design, it is possible to rapidly explore several genomicly-guided combinations that could speed the development process and potentially bring benefit to more patients," said Daniel D. Von Hoff, M.D.,
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Radiation Overdose at the Beatson Oncology Centre
2. Videoconferencing, an impetus to Pediatric Oncology
3. Oncology Drug Pemnat Launched By NATCO
4. United Biotech Launches New Oncology Division
5. Bengal Teenager to Participate in World Oncology Camp
6. CMPMedica Adds Oncology Search Engine to SearchMedica.com
7. Bird Flu: Orissa Initiates Protective Measures
8. Biota Initiates Drug Testing War against Common Cold
9. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
10. Government Initiates A Program To Curb HIV
11. Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...ementProvidesFinancialFlexibility,AllowingCompanyt...,Nov.25/PRNewswire-FirstCall/-LabopharmInc.(TSX:DD...ndbyequitydistributionagreement(SEDA)withYAGlobalM...nderthetermsoftheagreement,YAhascommittedtoprovide...abopharm,sdiscretion,throughthepurchaseofnewlyissu...
(Date:11/25/2009)...LIFFLAKE,N.J.,Nov.25/PRNewswire-FirstCall/--ParPha...dtheresultsofits"ModifiedDutchAuction"tenderoffer,...0aggregateprincipalamount,oruptoapproximately82.7%...leNotesdue2010. ,, BasedonthecountbyAmericanSto...etenderoffer,$30,805,000aggregateprincipalamountof...
(Date:11/25/2009)...imate change by reducing carbon dioxide and other ... benefits in addition to reducing the risk of clim...cording to a series of six papers appearing today ... . , Two University of California, Berkeley, aut...lobal environmental health, and Michael Jerrett, a...
(Date:11/25/2009)...ke, cardiovascular disease may make a case for pop... WEDNESDAY, Nov. 25 (HealthDay News) -- It,s known...risk of high blood pressure. Now there,s confirmat...es to significantly greater risk of cardiovascular...he Nov. 25 online edition of BMJ found that a di...
(Date:11/25/2009)... Thirty-seven million Americans are af...ally invasive technology for treating chronic sinu...ter in Jackson, Miss. The Balloon Sinuplasty&trade... and balloon to quickly open and expand blocked si... 25, 2009 -- A clinically proven, minimally invasi...
Breaking Medicine News(10 mins):Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 2Health News:Labopharm Enters Into CAD$25 Million Standby Equity Distribution Agreement 3Health News:Par Pharmaceutical Announces Results of Its 'Modified Dutch Auction' Tender Offer 2Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 2Health News:Cutting greenhouse pollutants could directly save millions of lives worldwide 3Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 2Health News:Novel Technology in Treating Chronic Sinus Infections Available at Baptist 3
...2008) Results from a pivotal Phase III clinical t... an oral, once-daily, investigational anticoagulan...ood clots in patients who underwent total knee rep.... , Data from the RECORD4 clinical trial were pre...
...ay 30 Lutronic, Inc., one of,the world,s leading ...ems,announced today that its MOSAIC eCO2 system, t...s combining fractional technology with the deep,ab...atures,a contoured scanner hand piece with adjusta...
...options, TORONTO, May 30 /PRNewswire-FirstCall/ -... Amex: PME) today announced it has been notified b... will not continue to,support PreMD,s plan for reg...g application with the Securities and Exchange,Com...
...c women are less likely than white women to receiv...wing surgery for early breast cancer, according to...hers will present at the annual meeting of the Ame...d Hispanic breast cancer patients may be undertrea...
...researchers at The Ohio State University, in partn...eceived a $34 million grant from the National Inst...nical and translational protocols that help identi...nd Translational Science will provide support serv...
...e-FirstCall/ - Rami Liebenthal, Executive,Vice Pre...ng, is pleased to,announce the appointment of Don ...he U.S. market., Don joins IMRIS after spending 2...as well as the business,development of targeted he...
Other Medicine News:Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 2Health News:Rivaroxaban phase III pivotal data presented at EFORT annual meeting 3Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 2Health News:Soon to Be Released: Lutronic Announces the MOSAIC eCO2, the World's First 'Smart' Fractional CO2 Laser System for Treating Aesthetic and Dermatological Conditions, Will Soon Be Coming to the U.S. Market for Commercial Use 3Health News:Delisting Notification Received from the American Stock Exchange 2Health News:Blacks, Hispanics less likely than whites to receive follow-up radiation for early breast cancer 2Health News:Ohio State receives $34M NIH grant 2
(Date:11/24/2009)...Nov.24/PRNewswire-FirstCall/--Endologix,Inc.(Nasda...raorticdisorders,announcedtodaythatithasfiledamoti...fringementlawsuitbroughtagainstitinOctober2009byCo...ourtinIndianapolis,Indiana. ,, Endologixhasrequ...PatentandTrademarkOffice(USPTO)conductsproceedings...
(Date:11/24/2009)...N.J.andNEWYORK,Nov.24/PRNewswire/-- EisaiInc.andP...stration(FDA)hasacceptedforreviewEisai,sNewDrugApp...ilHClextendedrelease)tabletsforthetreatmentofmoder...eformulationcontains23mgofdonepezilHClinanextended...lowsforgradualreleaseofthedrug.TheNDAisbasedonahea...
(Date:11/24/2009)...,Nov.24/PRNewswire/--ZargisMedicalCorp.,asubsidiar...ensCorporateResearch(NYSE: SI ),todayannouncedthat...4,2009episodeofCBS, TheEarlyShow duringasegmentinw...,reviewedfivewinningproductsfromthepublication,s20...widely-viewedtelevisionmorningnewstalkshowbroadcas...
Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3NAMSA Unveils New Larger State of the Art Analytical Chemistry Facility 58105 1NAMSA Unveils New Larger State of the Art Analytical Chemistry Facility 58105 2New stove dramatically improves lung health in Mexican women 58102 1New stove dramatically improves lung health in Mexican women 58102 2New stove dramatically improves lung health in Mexican women 58102 3Monarch Labs to Demonstrate Maggot Therapy at Diabetic Limb Salvage Conference 58099 1Monarch Labs to Demonstrate Maggot Therapy at Diabetic Limb Salvage Conference 58099 2Monarch Labs to Demonstrate Maggot Therapy at Diabetic Limb Salvage Conference 58099 3
...rs Hope for Treatment of,Children, WHITE PLAINS, ...ssfully prevented a rare craniofacial birth defect...he same disorder, according,to new research funded...ch is being published in the journal Nature Medici...c research into new,treatments, said Michael Katz,...
...ses patients with diabetes to,maintain good contro...ANDRIA, Va., Feb. 6 In response to,today,s announ...itute,which sponsors the ACCORD (Action to Control...e intensive blood glucose (sugar) control,sub-stud...iabetes,Association strongly encourages people wit...
Other Medicine Technology:Molecular Therapy Succeeds in Preventing Craniofacial Birth Defect in Mice 2Statement from the American Diabetes Association Related to ACCORD Trial Announcement 2Statement from the American Diabetes Association Related to ACCORD Trial Announcement 3
The Ultima 2000 SE Argon Laser System
VISULAS 532s
Kremer Fixation Forceps
...method for determining color vision abnormalities ...e data which can be applied to many psychological ...ists of four trays containing a total of 85 remova... variation on one side and are numbered on the rev...
Medicine Products: